Physician profile
Kevin Le
NPI 1740890300
$1,004.34
in general payments reported to CMS, 2019-2025
11 companies · $34.13 in 2025
The $34.13 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.41 · 2022: $507 · 2023: $159 · 2024: $275 · 2025: $34.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $314.40 | 2022-2025 | Infuse |
| Glaukos Corporation | $162.37 | 2022 | |
| Coopervision INC. | $123.70 | 2022-2023 | Myday Contact Lens, Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $111.49 | 2024 | Xdemvy |
| Rxsight INC | $103.81 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $55.54 | 2022-2023 | Acuvue |
| Alcon Vision LLC | $34.29 | 2023-2025 | Precision7, Total30 |
| Spark Therapeutics, INC. | $29.41 | 2019 | |
| Abbvie INC. | $27.55 | 2022 | |
| Oyster Point Pharma, INC. | $22.61 | 2024 | Tyrvaya |
| Allergan, INC. | $19.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.